[Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
OBJECTIVE
To assess the optinums chemotherapeutic protocols for higher CR rate in the treatment of intermediate and high grade malignant non Hodgin's lyphoma(NHL).


METHODS
Seventy-four patients with pathological intermediate and high grade malignant NHL were tried randomly with revised ProMACE-CytaBOM(treatment group) and CHOP(control group).


RESULTS
The CR rate was 56.8% in the treatment group and 35.0% in the control group (P > 0.05). In patients with high grade maliganat NHL, the CR rate of ProMACE-CytaBOM was 60.0% as compared with 32.0% of the CHOP (P < 0.05). Patients in both group suffered from similar side effects with tolerable bone marrow supression and gastric irritation.


CONCLUSIONS
ProMACE-CytaBOM is a safe regimen with relative high CR rate for high grade malignant NHL, but further research is indicated for remote results.
Wang
A
A
Department of Clinical Oncology, Hunan Cancer Hospital, Changsha.
Luo
Y
Y
Wang
Z
Z
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate